In this issue:
Natalizumab: personalised extended interval dosing
Ocrelizumab dampens vaccine responses
Real world evidence of aHSCT vs alemtuzumab for aggressive MS
Levetiracetam may improve upper limb dexterity in patients with cerebellar signs
Clinical characteristics of patients with MS and COVID-19
Management of MS during the COVID-19 pandemic
Hookworm treatment for relapsing MS
Is gadolinium always necessary for monitoring disease activity?
Age-related changes in ARR in adults with RRMS
Safety profile of shorterduration ocrelizumab infusion
Please login below to download this issue (PDF)